718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells

Autor:	Cong Li, Gregory Moore, Umesh Muchhal, John Desjarlais, Matthew Bernett, Madeline Fort, Lingming Liang, Tao Osgood, Rodolfo Yabut, Sarav Kaliyaperumal, John Harrold, Jude Canon, Anna Rogojina, Raushan Kurmasheva, Peter Houghton, Olivier Nolan-Stevaux
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Druh dokumentu:	article
ISSN:	2051-1426
DOI:	10.1136/jitc-2020-SITC2020.0718
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/9f44cfaebbde4a72a66c6cbe35d25b0b Zobrazit plný text záznamu View record in DOAJ